Coronaltitude - Multicentric Evaluation of the Impact on Hypoxia Sensitivity of Patients With COVID-19

NACompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

November 2, 2021

Study Completion Date

November 2, 2021

Conditions
Covid19SARS-CoV2 InfectionHypoxia, Altitude
Interventions
BIOLOGICAL

COVID19

"Intervention in experimental group (COVID+ group) is the disease itself, compared to the control group (COVID- group). At inclusion, subjects have been asked if they have suffered COVID19 in the 12 months before inclusion, during whichever wave, attested by a positive PCR, positive serology test or positive chest CT scan.~Moreover, the Richalet test is a cardiorespiratory exercise test on an ergocycle (an electrically braked cycloergometer), whilst continuous measurement by a 12-lead ECG, a blood pressure cuff, a metabograph and an ear pulse oximeter. This, to assess cardiac response, ventilatory response and relevant metabolic parameters (CF, RR, SpO2, volume, BP). Subjects breathes through a mask connected to a gas mixer, which provides a gas mixture with 11,5% oxygen (corresponding to ambient air at an altitude of 4800m) in the hypoxia phases."

Trial Locations (1)

74400

Institut de Formation et de Recherche en Médecine de Montagne (IFREMMONT), Chamonix

All Listed Sponsors
collaborator

University of Paris 13

OTHER

collaborator

Ecole Nationale des Sports de Montagne

OTHER

lead

Institut de Formation et de Recherche en Médecine de Montagne

OTHER

NCT05167357 - Coronaltitude - Multicentric Evaluation of the Impact on Hypoxia Sensitivity of Patients With COVID-19 | Biotech Hunter | Biotech Hunter